Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 2/20 | 0.39 |
| ▸ | FNTB | P49356 | 2/20 | 0.39 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.39 |
| ▸ | NPY4R | P50391 | 7/20 | 0.39 |
| ▸ | NPY1R | P25929 | 4/20 | 0.39 |
| ▸ | NPY2R | P49146 | 4/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.36 |
| ▸ | GNPAT | O15228 | 1/20 | 0.36 |
| ▸ | TFPI | P10646 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30753507 | 1.00 | PTGS1 (0.40) | PTGS1GSTK1FNTAFNTBPGGT1B | |
| SCHEMBL25639021 | 1.00 | PTGS1 (0.40) | PTGS1GSTK1FNTAFNTBPGGT1B | |
| SCHEMBL30753508 | 0.98 | PTGS1 (0.43) | PTGS1GSTK1FNTAFNTBPGGT1B | |
| SCHEMBL29568701 | 0.94 | PTGS1 (0.43) | PTGS1GSTK1FNTAFNTBPGGT1B | |
| SCHEMBL30767724 | 0.94 | PTGS1 (0.43) | PTGS1GSTK1FNTAFNTBPGGT1B | |
| SCHEMBL30509913 | 0.94 | PTGS1 (0.43) | PTGS1GSTK1FNTAFNTBPGGT1B | |
| SCHEMBL30509912 | 0.94 | PTGS1 (0.43) | PTGS1GSTK1FNTAFNTBPGGT1B | |
| SCHEMBL30695170 | 0.93 | PTGS1 (0.43) | PTGS1GSTK1FNTAFNTBPGGT1B | |
| SCHEMBL5849470 | 0.91 | OPRL1 (0.40) | NPY4RNPY1RNPY2RNPY5ROPRL1 | |
| SCHEMBL5849482 | 0.91 | OPRL1 (0.40) | NPY4RNPY1RNPY2RNPY5ROPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540154-B2 | Glucosamine derivative nanoparticle and preparating method and use thereof | CPC CORPORATION, TAIWAN (TW) | 2026-02-03 | — | — | US | claimed |
| EP-4400099-B1 | GLUCOSAMINE DERIVATIVE NANOPARTICLE AND PREPARATION METHOD AND USE THEREOF | CPC CORP TAIWAN (TW) | 2026-01-14 | — | — | EP | claimed |
| EP-4400099-A1 | GLUCOSAMINE DERIVATIVE NANOPARTICLE AND PREPARATION METHOD AND USE THEREOF | CPC Corporation, Taiwan (TW) | 2024-07-17 | — | — | EP | claimed |
| US-20240228525-A1 | GLUCOSAMINE DERIVATIVE NANOPARTICLE AND PREPARATING METHOD AND USE THEREOF | CPC CORPORATION, TAIWAN (TW) | 2024-07-11 | — | — | US | claimed |
| CN-115518165-A | Application of PAD4 inhibitor loaded by CRGD sequence peptide modified chitosan in preparation of anti-tumor metastasis drugs | 首都医科大学 | 2022-12-27 | — | — | CN | claimed |
| US-12630683-B2 | Medical device with tunable hydrophobicity and method of manufacture | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12540154-B2 | Glucosamine derivative nanoparticle and preparating method and use thereof | CPC CORPORATION, TAIWAN (TW) | 2026-02-03 | — | — | US | disclosed |
| EP-4400099-B1 | GLUCOSAMINE DERIVATIVE NANOPARTICLE AND PREPARATION METHOD AND USE THEREOF | CPC CORP TAIWAN (TW) | 2026-01-14 | — | — | EP | disclosed |
| CN-119546353-A | Medical device with adjustable hydrophobicity and method of manufacture | 波士顿科学医学有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4400099-A1 | GLUCOSAMINE DERIVATIVE NANOPARTICLE AND PREPARATION METHOD AND USE THEREOF | CPC Corporation, Taiwan (TW) | 2024-07-17 | — | — | EP | disclosed |
| US-20240228525-A1 | GLUCOSAMINE DERIVATIVE NANOPARTICLE AND PREPARATING METHOD AND USE THEREOF | CPC CORPORATION, TAIWAN (TW) | 2024-07-11 | — | — | US | disclosed |
| US-20240043643-A1 | MEDICAL DEVICE WITH TUNABLE HYDROPHOBICITY AND METHOD OF MANUFACTURE | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-11331415-B2 | Supramolecular alginate materials for biomedical applications | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2022-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540154-B2 | Glucosamine derivative nanoparticle and preparating method and use thereof | CSGALNACT1, COLGALT1, FUT6 | PTGS1 1760/4885GSTK1 3229/4885FNTA 3703/4885 |
| US-12630683-B2 | Medical device with tunable hydrophobicity and method of manufacture | CD44, SELE, GFER | PTGS1 887/4885GSTK1 948/4885FNTA 1064/4885 |
| US-20240228525-A1 | GLUCOSAMINE DERIVATIVE NANOPARTICLE AND PREPARATING METHOD AND USE THEREOF | UGGT1, CSGALNACT1, OGT | PTGS1 1040/4885GSTK1 1187/4885FNTA 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.